MAPT and Alzheimer disease: Wang et al. (2023) suggest overexpression of the HS3ST1 gene, a member of the HS biosynthetic enzyme family, may enhance Tau pathology spread, presenting a novel therapeutic target for AD (Wang et al. 2023).